亚洲精品国产成人一区二区_欧美性xxxxx极品娇小_国产欧美久久一区二区三区_日日麻批免费40分钟无码

Mabwell's Anti-CD47/PD-L1 Bispecific Antibody 6MW3211 Receives IND Approval in China

Release time:Jul 21, 2021

July 21, 2021, Shanghai— Mabwell Bioscience Co., Ltd. ("Mabwell") , an innovative biopharmaceutical company with a whole industrial chain, announced today that its IND application for 6MW3211, an anti-CD47/PD-L1 bispecific antibody drug candidate, has been formally approved by the Center for Drug Evaluation (CDE) of China National Medical Products Administration. The clinical trials will be conducted for late-stage malignant tumor.

6MW3211 is a Class I drug candidate developed by Mabwell. It is designed to selectively bind to CD47 and PD-L1 on tumor cells to attenuate CD47-SIRPα signal and block the PD-1/PD-L1 checkpoint inhibition, thereby triggering stronger tumor cell phagocytosis and enhancing T cell activation. The IgG-like structure with a common light chain is the strategy to overcome pairing problem and simplify the production process. In addition, 6MW3211 specifically binds to CD47 on tumor cells, but doesn’t bind to erythrocytes of humans and monkeys, suggesting that 6MW3211 has a good safety potential for erythrocytes. A comprehensive battery of nonclinical studies has been designed and conducted to evaluate the target binding characteristics, mechanism of action, anti-cancer efficacy and safety to support the proposed clinical trial.

主站蜘蛛池模板: 元朗区| 高阳县| 博兴县| 临清市| 安徽省| 包头市| 聂拉木县| 上杭县| 孙吴县| 偏关县| 阳曲县| 和林格尔县| 四川省| 玛曲县| 凌源市| 醴陵市| 萝北县| 怀集县| 新竹县| 荔波县| 谷城县| 丰县| 招远市| 墨江| 嘉黎县| 平乐县| 施甸县| 阳江市| 栾城县| 滁州市| 宣化县| 巫山县| 渭源县| 临猗县| 若尔盖县| 清丰县| 大渡口区| 济阳县| 龙井市| 龙岩市| 海阳市|